Goldman Sachs16 min
Walter Isaacson, Historian and Author of "The Code Breaker"
Walter Isaacson, Jennifer Doudna, John Rogers
Fireside Chat, Interview, Conference Presentation, Product Demonstration
Jennifer Doudna's Background and Scientific Path
- Born in Hawaii as a Polynesian outsider, Doudna was motivated by a sense of "not fitting in" that drove her scientific curiosity and reclusive nature.
- Inspired by James Watson's "The Double Helix" in sixth grade, she identified with Rosalind Franklin's treatment and decided to pursue science despite a school counselor's discouragement.
- At Pomona College and Harvard, Doudna focused on RNA structure, recognizing it as more functionally useful than DNA for building proteins and guiding enzymes.
- Doudna and co-inventor Emmanuelle Charpentier won the 2020 Nobel Prize in Chemistry for developing the CRISPR gene-editing tool.
- The technology's ability to use RNA as a messenger is the foundational mechanism behind the Pfizer and Moderna mRNA vaccines.
Competition vs. Collaboration in Scientific Research
- Walter Isaacson argues that intense competition, while sometimes bitter, ultimately spurs the human race forward in fields like journalism, finance, and science.
- The high stakes of gene editing have created a "first past the post" system involving rivalries such as Watson/Crick vs. Linus Pauling and Doudna vs. Feng Zhang.
- Isaacson notes a 20-30 year distortion in science where the race for patents and prizes reduced collegiality and collaboration.
- The onset of the coronavirus pandemic acted as a restorative force, prompting rival teams in the Bay Area and Cambridge to temporarily set aside IP claims to share data openly.
- The crisis demonstrated that intense competition can coexist with a higher purpose: helping the human species through immediate crisis response.
Historical Progression of Genetic Research
- Modern medical research evolved from Darwin and Mendel (1850s) discovering the gene to Watson and Crick (1953) discovering the DNA structure.
- The Human Genome Project (2000) sequenced the entire human genome, allowing scientists to read DNA but not yet edit it.
- The 2012 CRISPR breakthrough provided the ability to "cut and edit" genes, moving research from observation to intervention.
- This transition mirrors physics' historical shifts, moving from theoretical understanding to practical application.
Ethical Dilemmas and Future Risks
- Isaacson distinguishes between state-sponsored eugenics (like Nazi Germany), which he believes is unlikely to recur, and "free-market eugenics" driven by individual consumer choice.
- A "free market" scenario poses a risk of reducing societal diversity through commercial selection for traits like height, eye color, or even sexual orientation.
- Isaacson proposes a case-by-case ethical framework:
- Permissible: Editing to eliminate debilitating serious diseases (e.g., sickle cell, Tay-Sachs, Huntington's, cystic fibrosis).
- Problematic: Enhancements that improve mental capacity, endurance, or personality traits, which could exacerbate inequality.
- Complex: Editing personality dispositions (e.g., susceptibility to schizophrenia), for which he admits there is no clear right answer.
- Recent events, such as the 2018 case of gene-edited twins in China, highlight the risks of rogue actors and "slippery slopes" in gene editing.
Nobel Prize Controversy and Future Awards
- The 2020 Nobel Prize in Chemistry was awarded solely to Doudna and Charpentier for discovering the basic chemistry of CRISPR.
- Feng Zhang was excluded because the prize committee viewed his work as the application of CRISPR to human cells rather than the fundamental chemical discovery.
- Isaacson predicts the Nobel Prize in Medicine may eventually be awarded to:
- Feng Zhang.
- George Church.
- David Liu (for base editing and prime editing).
- Isaacson anticipates a delay in the next award to allow time for the success of medical applications of CRISPR to become established.